This is a critically important editorial (The Guardian view on mRNA vaccines: they are the future – with or without Donald Trump, 1 January). I have just gained at least a year of life from a trial of a new mRNA off-the-shelf “vaccine” (neoantigen therapeutic), to which I turned after receiving the message “no options left”.
A dual American and British citizen and academic, I was a researcher, university professor and policy adviser in Russia, and because of the cost of treatment in the US, I returned to the UK in 2019 after being diagnosed with an incurable melanoma of the nasal mucosa. In the UK, I underwent surgery and was given immunotherapy, the most advanced treatment then available. After recurrence, when further surgery was ruled out, I sent an email to the remarkable head of the mRNA trial, Dr David Pinato of Imperial College, who suggested I apply for recruitment by his team at Hammersmith hospital. My tumours are now virtually gone.
